Does Rallies show Form 4 insider transactions for PYXS?

Yes. Rallies tracks PYXS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PYXS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PYXS. It does not provide personalized investment advice.

PYXS (Pyxis Oncology, Inc. Common Stock) Stock Analysis - Insider Trades

Pyxis Oncology, Inc. Common Stock (PYXS) is a publicly traded Healthcare sector company. As of May 21, 2026, PYXS trades at $2.00 with a market cap of $127.98M and a P/E ratio of -1.47. PYXS moved +4.71% today. Year to date, PYXS is +65.29%; over the trailing twelve months it is +65.29%. Its 52-week range spans $0.83 to $5.55. Analyst consensus is strong buy with an average price target of $6.33. Rallies surfaces PYXS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PYXS stock inside the company?

Recent PYXS insider activity includes HUMPHREY RACHEL sold 13.90K, HUMPHREY RACHEL sold 200, HUMPHREY RACHEL sold 1.40K, Connealy Pamela Ann bought 5.45K, and Connealy Pamela Ann bought 83.40K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PYXS Key Metrics

Key financial metrics for PYXS
Metric	Value
Price	$2.00
Market Cap	$127.98M
P/E Ratio	-1.47
EPS	$-1.31
Dividend Yield	0.00%
52-Week High	$5.55
52-Week Low	$0.83
Volume	0
Avg Volume	0
Revenue (TTM)	$13.86M
Net Income	$-81.73M
Gross Margin	0.00%

Recent PYXS Insider Trades

HUMPHREY RACHEL sold 13.90K (~$14.36K) on Apr 21, 2025.
HUMPHREY RACHEL sold 200 (~$194) on Apr 17, 2025.
HUMPHREY RACHEL sold 1.40K (~$1.36K) on Apr 14, 2025.
Connealy Pamela Ann bought 5.45K (~$10.90K) on Nov 26, 2024.
Connealy Pamela Ann bought 83.40K (~$163.46K) on Nov 26, 2024.

Latest PYXS News

Pyxis Oncology Completes Q1 Enrollment, Targets Mid-Year 5.4 mg/kg MICVO Data — May 14, 2026
Pyxis Oncology Appoints ADC Expert Nelson Azoulay to Advance Lead Clinical Asset — May 7, 2026
Pyxis Oncology’s maMICVO Demonstrates Synergistic Tumor Inhibition with Anti-PD-1 — Apr 17, 2026
Pyxis Oncology Completes Phase 1 MICVO Enrollment, Reports 46% Monotherapy ORR and 71% Combo ORR — Mar 23, 2026

PYXS Analyst Consensus

7 analysts cover PYXS: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.33.

Common questions about PYXS

Who is trading PYXS stock inside the company?: Recent PYXS insider activity includes HUMPHREY RACHEL sold 13.90K, HUMPHREY RACHEL sold 200, HUMPHREY RACHEL sold 1.40K, Connealy Pamela Ann bought 5.45K, and Connealy Pamela Ann bought 83.40K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PYXS?: Yes. Rallies tracks PYXS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PYXS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PYXS. It does not provide personalized investment advice.